As of September 30, 2024, Oragenics, Inc. reported total assets of $5.2 million, an increase from $4.97 million at the end of 2023. Current assets rose to $4.11 million, up from $3.87 million. However, total liabilities also increased to $2.13 million from $1.80 million, resulting in a decrease in shareholders' equity to $3.08 million from $3.17 million.

In terms of revenue, Oragenics reported no grant revenue for the third quarter of 2024, a significant decline from $7,466 in Q3 2023. For the nine months ending September 30, 2024, grant revenue was also absent, compared to $37,653 in the same period of the previous year. Total operating expenses for Q3 2024 were $2.44 million, up from $2.10 million in Q3 2023, while total operating expenses for the nine months decreased to $7.20 million from $8.15 million year-over-year. The company reported a net loss of $2.46 million for Q3 2024, compared to a loss of $2.01 million in Q3 2023. The net loss for the nine months ended September 30, 2024, was $7.22 million, an improvement from $7.91 million in the prior year.

Oragenics has focused its efforts on the development of ONP-002, a product candidate for treating mild traumatic brain injury (mTBI). The company has suspended its previous vaccine and lantibiotic programs to allocate resources towards ONP-002. Research and development expenses for ONP-002 were approximately $2.4 million for the nine months ended September 30, 2024, a decrease from $4.45 million in the same period of 2023.

The company has engaged in several financing activities, raising approximately $6.67 million from the issuance of common stock in the nine months ended September 30, 2024, compared to $849,808 in the same period of 2023. Cash provided by financing activities increased significantly to $6.24 million from $464,479 year-over-year. However, the company reported a net decrease in cash and cash equivalents of $339,452 for the nine months, a notable improvement from a decrease of $5.66 million in the prior year.

Oragenics has implemented cost-saving measures, including staff reductions and the termination of its corporate office lease in Tampa, Florida, to manage cash flow. The company has expressed substantial doubt about its ability to continue operations beyond Q4 2024 without additional financing. As of September 30, 2024, the company had an accumulated deficit of $213.44 million and is actively seeking further funding to support its operations and the development of ONP-002.